These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 28222215)

  • 21. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
    Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
    Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.
    Li J; Chen QY; Mo H; Zhang YL; Huang ZF; Zeng YX
    Int J Biol Sci; 2011; 7(5):607-17. PubMed ID: 21614153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
    Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
    Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epstein-Barr virus early ribonucleic acids as a diagnostic adjunct for relapsed metastatic tumors in patients with cured primary undifferentiated nasopharyngeal carcinoma.
    Ho CL; Lee SH; Chen LM; Chao TY
    Am J Otolaryngol; 2000; 21(2):80-4. PubMed ID: 10758991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma.
    Chen WH; Tang LQ; Zhang L; Chen QY; Guo SS; Liu LT; Fan W; Zhang X; Guo L; Zhao C; Cao KJ; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
    Oncotarget; 2015 Nov; 6(35):38296-307. PubMed ID: 26512922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
    Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
    BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy.
    An X; Wang FH; Ding PR; Deng L; Jiang WQ; Zhang L; Shao JY; Li YH
    Cancer; 2011 Aug; 117(16):3750-7. PubMed ID: 21319149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
    Wang WY; Twu CW; Lin WY; Jiang RS; Liang KL; Chen KW; Wu CT; Shih YT; Lin JC
    Cancer; 2011 Oct; 117(19):4452-9. PubMed ID: 21437892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q; Burton R; Reddy V; Lucas KG
    Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.
    Toh HC; Yang MH; Wang HM; Hsieh CY; Chitapanarux I; Ho KF; Hong RL; Ang MK; Colevas AD; Sirachainan E; Lertbutsayanukul C; Ho GF; Nadler E; Algazi A; Lulla P; Wirth LJ; Wirasorn K; Liu YC; Ang SF; Low SHJ; Tho LM; Hasbullah HH; Brenner MK; Wang WW; Ong WS; Tan SH; Horak I; Ding C; Myo A; Samol J
    Ann Oncol; 2024 Dec; 35(12):1181-1190. PubMed ID: 39241963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of transoral nasopharyngeal brush biopsy for Epstein-Barr virus DNA detection of local recurrence of nasopharyngeal carcinoma after radiotherapy.
    Lam JW; Chan JY; Ho WK; Tsang RK
    Head Neck; 2016 Apr; 38 Suppl 1():E1301-4. PubMed ID: 26394721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined transfection with EBV-specific epitopes and HLA-A2 genes is more effective than separate transfection in promoting CTL lysis against nasopharyngeal carcinoma.
    Ding W; Fong C
    Cell Mol Immunol; 2004 Jun; 1(3):229-34. PubMed ID: 16219173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro induced and expanded Epstein Barr virus-specific cytotoxic T lymphocytes can specifically kill nasopharyngeal carcinoma cells].
    Chen LP; Huang JQ; Zhou TC; Zhang SX; Wang JL
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1431-3. PubMed ID: 18753079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma.
    Chan SC; Chang KP; Fang YD; Tsang NM; Ng SH; Hsu CL; Liao CT; Yen TC
    Laryngoscope; 2017 Jan; 127(1):E22-E28. PubMed ID: 27435352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
    Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
    Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
    Kalpoe JS; Dekker PB; van Krieken JH; Baatenburg de Jong RJ; Kroes AC
    J Clin Pathol; 2006 May; 59(5):537-41. PubMed ID: 16489178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
    Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
    Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma.
    Lutzky VP; Crooks P; Morrison L; Stevens N; Davis JE; Corban M; Hall D; Panizza B; Coman WB; Coman S; Moss DJ
    Clin Vaccine Immunol; 2014 Feb; 21(2):256-9. PubMed ID: 24351754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
    Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
    Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy.
    He J; Tang XF; Chen QY; Mai HQ; Huang ZF; Li J; Zeng YX
    Chin J Cancer; 2012 Jun; 31(6):287-94. PubMed ID: 22257383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.